FDA approves a new beta blocker

Dec 18, 2007

The U.S. Food and Drug Administration has approved Bystolic, a beta blocker, for the treatment of high blood pressure. Bystolic (nebivolol) is a new drug not previously approved for use in the United States.

Beta blockers are a well-established class of medications that reduce blood pressure by reducing the force with which the heart pumps, the FDA said. Nearly 1-in-3 adults in the United States suffers from hypertension, which can increase the risks for stroke, heart failure, heart attack, kidney failure, and death.

The FDA said the safety and efficacy of Bystolic was assessed during three randomized, double-blind, multi-center, placebo-controlled clinical trials that ran for up to three months. A fourth placebo-controlled clinical trial demonstrated additional blood pressure-lowering effects when Bystolic was given with up to two other antihypertensive medications in patients with inadequate blood pressure control.

More than 2,000 people received Bystolic during the trials, the FDA said, with the most common side effects reported being headache, fatigue, dizziness and diarrhea.

Mylan Bertek Pharmaceuticals Inc. of Research Triangle Park, N.C., is the sponsor of Bystolic. New York City-based Forest Laboratories Inc. owns the rights for marketing of the drug.

Copyright 2007 by United Press International

Explore further: Flu vaccine may hold key to preventing heart disease

add to favorites email to friend print save as pdf

Related Stories

Tuning light to kill deep cancer tumors

28 minutes ago

An international group of scientists led by Gang Han, PhD, at the University of Massachusetts Medical School, has combined a new type of nanoparticle with an FDA-approved photodynamic therapy to effectively kill deep-set ...

A global natural gas boom alone won't slow climate change

49 minutes ago

A new analysis of global energy use, economics and the climate shows that without new climate policies, expanding the current bounty of inexpensive natural gas alone would not slow the growth of global greenhouse ...

Researchers develop world's thinnest electric generator

49 minutes ago

Researchers from Columbia Engineering and the Georgia Institute of Technology report today that they have made the first experimental observation of piezoelectricity and the piezotronic effect in an atomically ...

US Supreme Court weighs generic drug dispute

1 hour ago

(AP)—The US Supreme Court seems divided as it considers a high-stakes patent dispute between rival pharmaceutical companies over the world's best-selling multiple sclerosis treatment.

Recommended for you

Supercomputers link proteins to drug side effects

21 hours ago

New medications created by pharmaceutical companies have helped millions of Americans alleviate pain and suffering from their medical conditions. However, the drug creation process often misses many side ...

No added benefit proven for umeclidinium/vilanterol in COPD

Oct 20, 2014

The drug combination umeclidinium/vilanterol (trade name Anoro) has been approved since May 2014 for adults with chronic obstructive pulmonary disease (COPD). In an early benefit assessment pursuant to the Act on the Reform ...

User comments : 0